Prognostic Values of PET/CT Findings and Tumor/Patient Characteristics with Non-Small Cell Lung Cancer
Prognostic Values of PET/CT Findings and Tumor/Patient Characteristics with Non-Small Cell Lung Cancer作者机构：Istanbul Bilim University Department of Thoracic Surgery Istanbul Turkey Istanbul University Cerrahpasa Medical School Department of Chest Diseases Istanbul Turkey Istanbul University Cerrahpasa Medical School Department of Nuclear Medicine Istanbul Turkey
出 版 物：《Open Journal of Respiratory Diseases》 (呼吸病期刊（英文）)
年 卷 期：2012年第2卷第4期
页 面：101-106页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Non-Small Cell Lung Cancer Survival Prognosis Positron Emission Tomography (PET) FDG-PET
摘 要：Background/Aim: Although numerous prognostic factors have been described for non-small cell lung cancer (NSCLC), there is still a requirement for better and non-invasive markers. FDG-PET is a non invasive diagnostic tool that is being used increasingly in the diagnosis of lung cancer. This study evaluates the prognostic values of PET/CT defined SUV measurements and other patient/tumor characteristics in newly diagnosed stage IIIB and IV NSCLC. Method: This ret- rospective study included 111 patients admitted between 2005 and 2006 with stage IIIB and IV NSCLC, whose diag- noses were verified with biopsy and staging performed with PET/CT. The prognostic values of standart uptake values (SUV) of the primary lesion on PET/CT, and other patient/tumor characteristics were analyzed using survival analysis. Results: SUV was found to be unrelated with survival. Only the presence of distant metastasis, type of metastasis (bone, brain, or the contralateral lung) and the type of radiotherapy used (curative or palliative) were found to be related to survival. SUV values in epidermoid carcinoma were found to be significantly higher compared to adenocarcinoma (16.15 ± 7.18 and 12.32 ± 5.52, respectively, p = 0.021).Conclusion: Our findings do not support that SUV of the pri- mary lesion in inoperable NSCLC has a prognostic value with respect to survival. This condition may be explained by the inclusion of significantly advanced NSCLC patients who are known to have a low survival and a high mortality, and also the relatively small sampling size.
维普期刊数据库